Author

OBB Newsletter

  • Enter your e-mail address below to subscribe to the Orange Book Blog newsletter. If a new post is added during the day, you'll receive it by e-mail the next morning.

Enter your email address:

Delivered by FeedBurner

AddThis Feed Button

Calendar

Disclaimer

  • Orange Book Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of Orange Book Blog does not create an attorney-client relationship. Orange Book Blog is Aaron Barkoff's personal website and it is intended primarily for other attorneys. Orange Book Blog is not edited by McDonnell Boehnen Hulbert & Berghoff LLP ("MBHB") or its clients. Therefore, no part of Orange Book Blog--whether information, commentary, or other--may be attributed to MBHB or its clients. Readers should be aware that MBHB represents many companies in the pharmaceutical and biotechnology industries, and therefore Orange Book Blog may occasionally report on news that relates to MBHB clients. Orange Book Blog will always strive to be unbiased in its reporting. All information on Orange Book Blog should be double-checked for its accuracy and current applicability. -- © Aaron F. Barkoff 2006-08

« Warner Chilcott Settles Antitrust Suits Brought by States and Indirect Purchasers Concerning Ovcon 35 | Main | FDA Refuses to Approve Any ANDAs for Generic Norvasc Besides Mylan's--For Now »

April 17, 2007

Follow-on Biologics News

A number of interesting news reports concerning follow-on biologics have been published in recent days:

Posted by Aaron Barkoff in Biosimilars |

Comments

Post a comment

Comments are moderated, and will not appear on this weblog until the author has approved them.